The round includes $20 million in new capital and the conversion of $20 million in seed-round debt. Participants include several leading strategics, venture capital firms and family offices, with multiple seed investors reinvesting - underscoring strong confidence in the company's initial focus on ventricular tachycardia (VT) and the broader versatility of its technology.

Founded in 2022, Field Medical is advancing next-generation pulsed field ablation (PFA) technologies to address the complex needs of modern cardiac ablation. The company is led by Dr. Steven Mickelsen, a pioneer in pulsed electric field technology and a leading innovator in the field. His foundational work in PFA established the basis for modern advancements in the technology, which Field Medical continues to refine with its groundbreaking solutions. In 2024, Field Medical's technology was recognized by the FDA with Breakthrough Device Designation and inclusion in the TAP Pilot Program.